Understanding how radiation affects immune responses in cancer treatment
Dissecting the Role of Radiation in Regulation of MHC-I and Neoantigen Presentation
['FUNDING_FELLOWSHIP'] · DUKE UNIVERSITY · NIH-10994078
This study is looking at how radiation therapy might make immunotherapy work better for people with soft tissue sarcomas by helping the immune system recognize and attack the cancer more effectively.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10994078 on ClinicalTrials.gov |
What this research studies
This research investigates how radiation therapy can enhance the effectiveness of immunotherapy in treating soft tissue sarcomas. By using genetically engineered mouse models, the study aims to uncover the mechanisms by which radiation increases the presentation of tumor antigens, potentially improving patient responses to immune checkpoint inhibitors. The focus is on understanding the role of MHC-I molecules in this process, which could lead to better treatment strategies for patients who currently do not respond well to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with soft tissue sarcomas who are considering or currently undergoing immunotherapy.
Not a fit: Patients with cancers other than soft tissue sarcomas or those who are not candidates for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with soft tissue sarcomas, enhancing their response to immunotherapy.
How similar studies have performed: Previous research has shown that combining radiation with immunotherapy can enhance treatment responses, suggesting that this approach has potential based on existing evidence.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SU, CHANG — DUKE UNIVERSITY
- Study coordinator: SU, CHANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy